New Rochelle, NY, August 21, 2014--Mesenchymal stem cells (MSCs) are present in virtually every type of human tissue and may help in organ regeneration after injury. But the theory that MSCs are released from the bone marrow into the blood stream following organ damage, and migrate to the site of injury, has long been debated. M.J. Hoogduijn and colleagues provide conclusive evidence to resolve the controversy over the mobilization and migration of MSCs in humans in a new study published in Stem Cells and Development, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the Stem Cells and Development website.
In "No Evidence for Circulating Mesenchymal Stem Cells in Patients with Organ Injury," Hoogduijn and coauthors from Erasmus University Medical Center (Rotterdam, The Netherlands), describe the results of studies to detect MSCs in the blood of healthy individuals, of patients with end-stage renal disease, of patients with end-stage liver disease, and of heart transplant patients with organ rejection. Whereas they did not find MSCs in the circulation of these individuals, they did report the presence of MSCs in the blood of a patient suffering from severe trauma with multiple fractures. In the trauma patient, the circulating MSCs likely derived from disruption of the bone marrow caused by the fractures.
"We can add the simple but elegant work of Martin Hoogduijn to the pantheon of studies in stem cell research that skewer a long treasured tenet of faith and consign it to mythology," says Editor-in-Chief Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI.
About the Journal
Stem Cells and Development is an authoritative peer-reviewed journal published 24 times per year in print and online. The Journal is dedicated to communication and objective analysis of developments in the biology, characteristics, and therapeutic utility of stem cells, especially those of the hematopoietic system. A complete table of contents and free sample issue may be viewed on the Stem Cells and Development website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many areas of science and biomedical research, including Cellular Reprogramming, Tissue Engineering, and Human Gene Therapy. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 Phone: (914) 740-2100 (800) M-LIEBERT Fax: (914) 740-2101 http://www.liebertpub.com
Contact: Kathryn Ryan, Mary Ann Liebert, Inc., (914) 740-2100, email@example.com
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.